James R Rigas

Summary

Affiliation: Dartmouth Medical School
Country: USA

Publications

  1. ncbi request reprint Bexarotene and erlotinib for aerodigestive tract cancer
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Norris Cotton Cancer Center, Lebanon, NH, USA
    J Clin Oncol 23:8757-64. 2005
  2. ncbi request reprint Current treatment paradigms for locally advanced non-small cell lung cancer
    James R Rigas
    Dartmouth Medical School, Lebanon, NH 03756, USA
    J Thorac Oncol 2:S77-85. 2007
  3. ncbi request reprint Taxane-platinum combinations in advanced non-small cell lung cancer: a review
    James R Rigas
    Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
    Oncologist 9:16-23. 2004
  4. ncbi request reprint Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene
    James R Rigas
    Comprehensive Thoracic Oncology Program, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire 03756, USA
    Oncologist 10:22-33. 2005
  5. ncbi request reprint Docetaxel in the treatment of esophageal cancer
    James R Rigas
    The Comprehensive Thoracic Oncology Program, Norris Cotton Cancer Center and Dartmouth Medical School, Lebanon, NH 03755, USA
    Semin Oncol 32:S39-51. 2005
  6. pmc Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy
    Matthew D Wood
    Comprehensive Thoracic Oncology Program, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    J Thorac Oncol 8:487-94. 2013
  7. ncbi request reprint A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer
    Konstantin H Dragnev
    Sections of Hematology Oncology and Clinical Pharmacology, Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
    Clin Cancer Res 13:1794-800. 2007
  8. doi request reprint A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors
    Konstantin H Dragnev
    Section of Hematology Oncology, Department of Medicine, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA dragnev dartmouth edu
    Chemotherapy 56:135-41. 2010
  9. pmc Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
    Cancer Prev Res (Phila) 4:818-28. 2011
  10. ncbi request reprint Nonclassical retinoids and lung carcinogenesis
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Dartmouth Hitchcock Medical Center, Hanover, NH 03756, USA
    Clin Lung Cancer 6:237-44. 2005

Research Grants

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Bexarotene and erlotinib for aerodigestive tract cancer
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Norris Cotton Cancer Center, Lebanon, NH, USA
    J Clin Oncol 23:8757-64. 2005
    ..The rexinoid, bexarotene, represses cyclin D1 and EGFR expression in vitro. It was hypothesized that combining bexarotene with the EGFR inhibitor, erlotinib, would augment clinical activity...
  2. ncbi request reprint Current treatment paradigms for locally advanced non-small cell lung cancer
    James R Rigas
    Dartmouth Medical School, Lebanon, NH 03756, USA
    J Thorac Oncol 2:S77-85. 2007
    ..This article will review the current treatment strategies for stage III NSCLC...
  3. ncbi request reprint Taxane-platinum combinations in advanced non-small cell lung cancer: a review
    James R Rigas
    Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
    Oncologist 9:16-23. 2004
    ..As our use of these taxane-platinum combinations expands, these differences in survival, response rate, adverse events, and QOL will permit us to better balance our treatment goals for all patients with all stages of NSCLC...
  4. ncbi request reprint Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene
    James R Rigas
    Comprehensive Thoracic Oncology Program, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire 03756, USA
    Oncologist 10:22-33. 2005
    ..The purpose of this review is to explore the rationale for rexinoids in the treatment of malignancies and to discuss the clinical profile of bexarotene in the treatment of non-small cell lung cancer...
  5. ncbi request reprint Docetaxel in the treatment of esophageal cancer
    James R Rigas
    The Comprehensive Thoracic Oncology Program, Norris Cotton Cancer Center and Dartmouth Medical School, Lebanon, NH 03755, USA
    Semin Oncol 32:S39-51. 2005
    ..These antitumor effects have led to the evaluation of docetaxel as a single agent and in combination with other agents and modalities in patients with esophageal cancer. Results of relevant trials are reviewed herein...
  6. pmc Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy
    Matthew D Wood
    Comprehensive Thoracic Oncology Program, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    J Thorac Oncol 8:487-94. 2013
    ....
  7. ncbi request reprint A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer
    Konstantin H Dragnev
    Sections of Hematology Oncology and Clinical Pharmacology, Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
    Clin Cancer Res 13:1794-800. 2007
    ..The relationship between bexarotene levels and biomarker changes in tumor tissues has not been previously studied...
  8. doi request reprint A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors
    Konstantin H Dragnev
    Section of Hematology Oncology, Department of Medicine, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA dragnev dartmouth edu
    Chemotherapy 56:135-41. 2010
    ..A single-institution phase I trial to determine the feasibility of using filgrastim or pegfilgrastim to increase the dose intensity of biweekly docetaxel and gemcitabine...
  9. pmc Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
    Cancer Prev Res (Phila) 4:818-28. 2011
    ..Additional lung cancer therapy or prevention trials with this oral regimen are warranted...
  10. ncbi request reprint Nonclassical retinoids and lung carcinogenesis
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Dartmouth Hitchcock Medical Center, Hanover, NH 03756, USA
    Clin Lung Cancer 6:237-44. 2005
    ..Results from randomized phase III clinical trials in NSCLC will ultimately determine the impact for rexinoid-based therapy or chemoprevention for lung cancer...
  11. pmc A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients
    Tian Ma
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH, USA
    Chemotherapy 58:321-9. 2012
    ..ABT-751 is a novel antimitotic agent that exerted cytotoxic effects in preclinical studies. Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs...
  12. doi request reprint Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases
    Jonathan D Marotti
    Department of Pathology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Diagn Cytopathol 41:15-21. 2013
    ..039) correlated with the presence of EGFR mutations. The presence of necrosis (P = 0.030), squamoid features (P = 0.048), and poorly differentiated tumors (P = 0.025) were more likely to be identified in the KRAS positive group...
  13. ncbi request reprint Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer
    James R Rigas
    Dartmouth Medical School, 1 Medical Center Drive, Lebanon, NH 03756, USA
    Lung Cancer 50:S17-24. 2005
    ..A randomized trial is currently underway that compares concurrent chemoradiotherapy (using cisplatin and etoposide) followed by either docetaxel consolidation or no further therapy...
  14. ncbi request reprint Uncovering novel targets for cancer chemoprevention
    Konstantin H Dragnev
    Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
    Recent Results Cancer Res 174:235-43. 2007
    ..Taken together, these preclinical and clinical findings strongly implicate these cyclins as novel molecular pharmacological targets for cancer chemoprevention...
  15. doi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients
    Monic Roengvoraphoj
    Comprehensive Thoracic Oncology Program, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756 0001, USA The Geisel School of Medicine at Dartmouth, One Rope Ferry Road, Hanover, NH 03755 1404, USA Electronic address
    Cancer Treat Rev 39:839-50. 2013
    ....
  16. ncbi request reprint Chlorpheniramine for motion sickness
    Jay C Buckey
    Department of Medicine, Dartmouth Medical School, One Medical Center Dr, Lebanon, New Hampshire 03756, USA
    J Vestib Res 14:53-61. 2004
    ..Motion sickness remains a significant problem for travelers and for those involved in naval, aviation and space operations. Many motion sickness remedies are also sedating, making them undesirable in many settings...
  17. doi request reprint Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer
    Candice C Black
    Department of Pathology, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Lung 191:265-70. 2013
    ..The FoxP3 gene is a marker of Tregs and can be visualized with immunohistochemistry (IHC). We investigated the presence and pattern of Tregs in non-small-cell lung tumors to determine possible therapeutic targets in lung cancer...
  18. doi request reprint A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
    Trevor J Bayliss
    Dartmouth Hitchcock Medical Center, Comprehensive Thoracic Oncology Program, Norris Cotton Cancer Center, Lebanon, USA
    Expert Opin Biol Ther 11:1663-8. 2011
    ..IL-6 has been implicated in resistance of lung cancer to EGF inhibitors. A mAb therapy targeting IL-6 may be an effective treatment for the inflammatory microenvironment in lung cancer...
  19. doi request reprint Pemetrexed in advanced non-small-cell lung cancer
    Alexander D Fuld
    Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Expert Opin Pharmacother 11:1387-402. 2010
    ..In the past decade, pemetrexed has had an increasingly established role in the treatment of advanced NSCLC in both first- and second-line settings...
  20. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers
    W Jeffrey Petty
    Department of Pharmacology, Norris Cotton Cancer Center, Hanover, New Hampshire 03755, USA
    Clin Cancer Res 10:7547-54. 2004
    ..The current study sought to determine whether the EGFR TKI erlotinib repressed cyclin D1 protein expression in immortalized HBE cells, lung cancer cell lines, and clinical aerodigestive tract cancers...
  21. ncbi request reprint A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma
    J Marc Pipas
    Neuro Oncology Program, Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, 1 Medical Center Drive, New Hampshire, Lebanon, NH 03756, USA
    J Neurooncol 71:301-5. 2005
    ..We conducted a Phase II trial of these agents in combination with filgrastim (G-CSF) in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma...
  22. ncbi request reprint Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial
    Vera Hirsh
    Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada
    Am J Clin Oncol 30:245-51. 2007
    ..Many patients with metastatic nonsmall cell lung carcinoma (NSCLC) cannot tolerate intravenous chemotherapy. Orally active agents would be more convenient and thus could improve their quality of life...
  23. ncbi request reprint Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel
    Rene Bruno
    Drug Metabolism and Pharmacokinetics, Aventis Pharma SA, tri E2 325, 20 Avenue Raymond Aron, 92165 Antony Cedex, France
    Clin Cancer Res 9:1077-82. 2003
    ..To identify predictors of treatment outcome and survival in patients with non-small cell lung cancer (NSCLC) treated with docetaxel...
  24. ncbi request reprint Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10
    Carmela Pepe
    Division of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    J Clin Oncol 25:1553-61. 2007
    ..This retrospective study evaluated the influence of age on survival, adjuvant chemotherapy delivery, and toxicity in National Cancer Institute of Canada (NCIC) Clinical Trials Group study JBR.10...
  25. ncbi request reprint Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period
    Steven R Deitcher
    Section of Hematology and Coagulation Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Clin Appl Thromb Hemost 12:389-96. 2006
    ..Enoxaparin treatment was feasible, generally well tolerated, and effective for a 180-day period in the secondary prevention of venous thromboembolic events in patients with active malignancy...
  26. ncbi request reprint Regression of metastatic non-small cell lung cancer with low molecular weight heparin
    James T Loynes
    Thromb Haemost 88:686. 2002
  27. ncbi request reprint IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001
    Fred R Hirsch
    Department of Medical Oncology Pathology, University of Colorado Cancer Center, 4200 E Ninth Avenue, B 188, Denver, CO 80262, USA
    Lung Cancer 37:325-44. 2002

Research Grants1

  1. IASLC Biology and Prevention of Lung Cancer Workshop
    James Rigas; Fiscal Year: 2005
    ..Funds in the amount of $12,000 are requested to cover partial travel expenses for out-of-town speakers. ..